No, Do Not Give Voltaren (Diclofenac) After Ketorolac
Administering Voltaren (diclofenac) to a patient who has already received ketorolac is contraindicated due to the cumulative risk of serious NSAID-related adverse events, including gastrointestinal bleeding, cardiovascular thrombotic events, and renal failure.
Why This Combination is Contraindicated
The FDA label for ketorolac explicitly states: "Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects" 11. This is a black-box warning that applies to all NSAIDs, including diclofenac (Voltaren).
The Specific Risks of Combining NSAIDs
When you combine two NSAIDs, you multiply rather than add the following risks:
- Gastrointestinal complications: Both drugs inhibit COX enzymes and increase risk of peptic ulcers, bleeding, and perforation—effects that are synergistic, not additive 11
- Cardiovascular events: Diclofenac carries particularly high cardiovascular risk (RR 1.63 for vascular events, mortality RR 2.40) 2, and combining NSAIDs amplifies thrombotic event risk
- Renal failure: Both drugs reduce renal prostaglandin synthesis; concurrent use dramatically increases acute kidney injury risk 1
- Bleeding complications: Ketorolac inhibits platelet function, and adding diclofenac compounds this effect 1
What to Do Instead for Persistent Pain
If your patient still has pain after ketorolac:
Wait for ketorolac clearance: Ketorolac has a half-life of 5-6 hours. Wait at least 12-24 hours after the last ketorolac dose before considering any other NSAID
Use alternative analgesic classes immediately:
- Add or increase opioid analgesics (morphine, hydromorphone, oxycodone)
- Consider acetaminophen if not already given (different mechanism, no COX inhibition)
- Use adjuvant analgesics (gabapentin, pregabalin for neuropathic components)
- Consider regional anesthesia techniques if appropriate
Reassess the pain: Persistent pain despite ketorolac may indicate inadequate dosing, wrong mechanism targeted, or a complication requiring evaluation
Critical Timing Consideration
Ketorolac is approved for maximum 5 days of use and is intended for short-term management of acute pain 1. If pain persists beyond what ketorolac can manage, the solution is not to add another NSAID but to escalate to stronger analgesics or investigate the underlying cause.
Common Pitfall to Avoid
Do not rationalize that "different NSAIDs work differently" or that "the patient needs more anti-inflammatory effect." The FDA contraindication is absolute and based on cumulative toxicity, not on theoretical differences in COX-1/COX-2 selectivity. Research shows ketorolac and diclofenac have equivalent analgesic efficacy 345, so combining them provides no additional benefit while dramatically increasing harm.